Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lansoprazole + clarithromycin + tinidazole
- Development stage
- Unknown
- Lead developer
- Geneith Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Peptikit is a combination therapy marketed by Geneith Pharmaceuticals for the eradication of *Helicobacter pylori* and the treatment of associated gastrointestinal disorders, including gastric ulcers, duodenal ulcers, and gastritis. The product is presented as a combination pack containing three active ingredients: lansoprazole, clarithromycin, and tinidazole. Lansoprazole is a proton pump inhibitor (PPI) that reduces gastric acid secretion by covalently binding to the H+/K+-ATPase enzyme. Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 23S ribosomal RNA of the 50S subunit. Tinidazole is a nitroimidazole antibiotic that, upon reductive activation, causes DNA strand breakage and cell death in anaerobic bacteria. This triple-therapy approach provides synergistic efficacy in eliminating *H. pylori* infection while promoting the healing of the gastric and duodenal mucosa.
- Brand names
- Peptikit
- Other names
- Lansoprazole, Clarithromycin, Tinidazole
02
Targets
bacterial dsDNA (Bacterial double-stranded DNA)SWELL1 (Leucine-rich repeat-containing protein 8A)23S rRNA (23S ribosomal RNA)ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on lansoprazole + clarithromycin + tinidazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lansoprazole + clarithromycin + tinidazole.